ClinicalTrials.gg
CompletedNCT00269152Updated Aug 18, 2015Results posted

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-18.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
57th of 198
122 · median 58
Started
2005
with 17 others
Phase 2
115 of 213
4 open now
Registered
61st of 213
by date
Lead sponsor
26 of 213
Eli Lilly and Company

Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 57th largest by enrollment of the 198 interventional ones that give a count, is one of 18 that started in 2005, is one of 115 in phase 2, and was the 61st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in participants with completely resected, stage Ib or IIa/IIb non-small cell lung cancer (NSCLC).

A two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven non-small cell lung cancer stage Ib, IIa or IIb
  • Must have complete tumor resection by pneumonectomy or lobectomy
  • Must have been surgically proven to be N2 negative

Exclusion criteria

Exclusion Criteria:

  • Serious concomitant systemic disorder
  • Post-operative complications or other surgery related conditions
  • A prior other than NSCLC unless that malignancy was diagnosed and treated at least 5 years ago
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    A: Pemetrexed + Cisplatin

    Drug: pemetrexed · Drug: cisplatin

  • Experimental
    B: Pemetrexed + Carboplatin

    Drug: pemetrexed · Drug: carboplatin

Interventions

  • 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles

    Also known as: LY231514, Alimta

  • 75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles

  • area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles

06

What researchers measure

Primary outcomes

  1. The Feasibility of Post-Surgery Chemotherapy

    Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \>=Grade 3 at 30 days after last infusion.

    Time frame: every 21-day cycle for 4 cycles up to 30 days after last infusion

Secondary outcomes

  1. Grade III/IV Adverse Events

    Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.

    Time frame: every 21-day cycle for 4 cycles

  2. Overall Survival at 3 Years

    For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.

    Time frame: baseline to date of death from any cause, assessed at 3 years

  3. 3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years

    For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.

    Time frame: length of time disease free, assessed at 3 years

  4. Overall Survival at 6 Years

    For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.

    Time frame: Baseline to date of death from any cause assessed at 6 years

07

Results

Posted Jun 11, 2009
Limitations and caveats
A protocol amendment was approved after the trial original completed to allow for collection of additional overall survival data due to number of participants surviving at 3 years.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + CisplatinPemetrexed + Carboplatin
Started6359
Completed4549
Not completed1810
Withdrew: Adverse event93
Withdrew: Withdrawal by subject73
Withdrew: Physician decision23
Withdrew: Protocol violation01

Outcome measures

PrimaryThe Feasibility of Post-Surgery Chemotherapy

Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \>=Grade 3 at 30 days after last infusion.

Time frame:
every 21-day cycle for 4 cycles up to 30 days after last infusion
Reported as:
Number · participants
The Feasibility of Post-Surgery Chemotherapy
participantsPemetrexed + CisplatinPemetrexed + Carboplatin
Participants "feasible"3827
Non-feasible = Early Discontinuation186
Non-feasible = Lost to Follow-up12
Non-feasible = Remaining Grade 3/4 Toxicity43
Non-feasible = Underdosage (<95% intended dose)519
Statistical analysis
  • Pemetrexed + Cisplatin · Feasibility response rate (percentage): 59.4 · 95% CI 46.4 to 71.5
  • Pemetrexed + Carboplatin · Feasibility response rate (percentage): 50.0 · 95% CI 36.1 to 63.9
SecondaryGrade III/IV Adverse Events

Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.

Time frame:
every 21-day cycle for 4 cycles
Reported as:
Number · participants
Grade III/IV Adverse Events
participantsPemetrexed + CisplatinPemetrexed + Carboplatin
Neutropenia96
Anaemia03
Thrombocytopenia03
Febrile neutropenia02
Leukopenia01
Lymphopenia10
Neutrophil count decreased16
Haemoglobin count decreased02
Platelet count decreased11
White blood cell count decreased02
Asthenia42
Nausea30
Vomiting30
Fatigue02
Catheter related infection10
Gamma-glutamyltransferase increased10
Anorexia10
Hyperglycaemia10
Hyperkalaemia10
Psychotic disorder10
SecondaryOverall Survival at 3 Years

For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.

Time frame:
baseline to date of death from any cause, assessed at 3 years
Reported as:
Number · percent probability of survival (%)
Overall Survival at 3 Years
percent probability of survival (%)Pemetrexed + CisplatinPemetrexed + Carboplatin
Overall Survival at 3 Years82.0 (72.4 to 91.6)83.2 (73.2 to 93.2)
Secondary3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years

For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.

Time frame:
length of time disease free, assessed at 3 years
Reported as:
Number · probability of disease-free survival (%)
3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years
probability of disease-free survival (%)Pemetrexed + CisplatinPemetrexed + Carboplatin
3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years61.2 (48.3 to 74.0)67.3 (54.5 to 80.1)
SecondaryOverall Survival at 6 Years

For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.

Time frame:
Baseline to date of death from any cause assessed at 6 years
Reported as:
Number · percent probability of survival (%)
Overall Survival at 6 Years
percent probability of survival (%)Pemetrexed + CisplatinPemetrexed + Carboplatin
Overall Survival at 6 Years72.6 (59.3 to 85.9)83.2 (73.2 to 93.2)

Adverse events

Collected over baseline through four 21-day cycles and up to 30 days of follow-up after last infusion. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin—18/64 (28.1%)61/64 (95.3%)
Pemetrexed + Carboplatin—5/54 (9.3%)52/54 (96.3%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPemetrexed + CisplatinPemetrexed + Carboplatin
DyspnoeaRespiratory, thoracic and mediastinal disorders5/640/54
NauseaGastrointestinal disorders4/640/54
VomitingGastrointestinal disorders3/640/54
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/640/54
Febrile neutropeniaBlood and lymphatic system disorders0/642/54
NeutropeniaBlood and lymphatic system disorders2/640/54
Chest painGeneral disorders2/640/54
Splenic artery aneurysmGastrointestinal disorders0/641/54
BronchitisInfections and infestations1/641/54
Aortic aneurysmVascular disorders0/641/54
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPemetrexed + CisplatinPemetrexed + Carboplatin
NauseaGastrointestinal disorders40/6430/54
FatigueGeneral disorders23/6421/54
NeutropeniaBlood and lymphatic system disorders21/6415/54
VomitingGastrointestinal disorders21/6417/54
CoughRespiratory, thoracic and mediastinal disorders6/6416/54
ConstipationGastrointestinal disorders17/648/54
AnorexiaMetabolism and nutrition disorders10/6414/54
AstheniaGeneral disorders10/6413/54
AnaemiaBlood and lymphatic system disorders12/648/54
Neutrophil count decreasedInvestigations4/6410/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Mean60.6 ± 7.758.9 ± 7.259.7 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Female141832
Male494190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Caucasian6258120
African112
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
France12820
Spain7815
Germany444387
Curative Surgery Used
Curative Surgery Used(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Pneumonectomy9918
Lobectomy464692
Bi-lobectomy8412
Smoking History
Smoking History(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Yes5656112
No7310
Stage of Disease Prior to Tumor Resection
Stage of Disease Prior to Tumor Resection(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Stage Ia011
Stage Ib272653
Stage IIa6511
Stage IIb302555
Stage IIIa011
Unknown: could have been either Stage IIIb or IV011
Tumor Type at Initial Pathological Diagnosis
Tumor Type at Initial Pathological Diagnosis(participants)Pemetrexed + CisplatinPemetrexed + CarboplatinTotal
Adenocarcinoma of the Lung272350
Squamous Carcinoma of the Lung242044
Non-Small Cell Lung Cancer549
Mixed Cell (Squamous/Adeno) Carcinoma of Lung055
Large Cell Carcinoma of Lung5712
Bronchoalveolar Carcinoma202
08

Study locations

18 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bordeaux, 33076, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75571, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35033, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Priest En Jarez, 42270, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31059, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Berka, 99437, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bielefeld, D-33604, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Großhansdorf, D-22927, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halle, D-06120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, D-30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kassel, 34125, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Köln, D-51109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Loewenstein, 74245, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, D-55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mannheim, 68167, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28046, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santiago De Compostela, 15706, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Nov 2007 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2005
First posted
Dec 23, 2005
Start
Dec 2005
Primary completionActual
Nov 2007
CompletionActual
Jul 2013
Results first posted
Jun 11, 2009
Last update
Aug 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00269152
Responsible party
Sponsor
First posted
Dec 23, 2005
Start date
Dec 2005
Primary completion
Nov 2007
Completion
Jul 2013
Results posted
Jun 11, 2009
Last update
Aug 18, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Carboplatin

Start the discussion